CEO Alice Zhang Speaks at 2017 Healthcare + A.I. Conference Hosted by Xconomy
Alice Zhang speaks about Verge Genomics' A.I.-enabled approaches to drug discovery
November 9, 2017
SAN FRANCISCO — Verge Genomics CEO Alice Zhang was invited to speak on a panel featuring industry-leading researchers in genomics at the annual Healthcare + A.I. Northwest conference hosted by Xconomy. At the panel, titled "Will A.I. Help Discover and Personalize the Next Breakthrough Therapy?", Zhang discussed Verge's unique approach combining machine learning genomic network analysis with neurobiology to tackle neurodegenerative diseases.
The Xconomy Healthcare + A.I. series brings together an elite group of healthcare and A.I. leaders in various innovation hubs in the country to discuss the application of healthcare combined with A.I. Speakers and attendees include top business leaders, academics, investors, and more in the field.
About Verge Genomics
Verge is a next-generation drug discovery company that is using human genomic data to accelerate the discovery of treatments for neurodegeneration. Founded by scientists from leading neuro-genomics labs, the Verge team is 14 people including 12 Ph.D.’s in machine learning, neuroscience, applied math, biophysics, statistics, and computational biology from UCLA, Stanford, Oxford, and UCSF, two former professors, and two pharma veterans.